GKB Ophthalmics Ltd (533212)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, GKB Ophthalmics' revenue was ₹33.0 Cr (+2.3% year on year, +10.9% on the previous quarter), and net profit ₹1.8 Cr (against a loss a year earlier); the operating margin was 8.2%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹33.0 | +2.3% | +10.9% |
| Operating profit | ₹2.7 | +238.3% | -12.1% |
| Net profit | ₹1.8 | from loss | +64.9% |
| EPS (₹) | 2.00 | from loss | +426.3% |
| Operating margin | 8.2% | — | — |
📢 Recent Corporate Announcements
GKB Ophthalmics reported a 26.5% YoY decline in standalone revenue to ₹6.40 Cr for Q1 FY27. However, the standalone net loss narrowed significantly to ₹0.50 Cr from a loss of ₹2.14 Cr in the same quarter last year, aided by a reduction in total expenses from ₹10.97 Cr to ₹7.61 Cr. A key development is the receipt of ₹11.70 Cr from the voluntary winding up of its subsidiary GSV Ophthalmics, which represents approximately 15.6% of the company's current market capitalization. The company also completed the closure of its step-down subsidiary, Prime Ophthalmics Products PTY Ltd, resulting in a ₹43.50 lakh write-off.
- Standalone revenue for Q1 FY27 stood at ₹6.40 Cr, down from ₹8.71 Cr in Q1 FY26.
- Standalone net loss narrowed to ₹0.50 Cr compared to a loss of ₹2.14 Cr in the previous year's quarter.
- Received ₹11.70 Cr cash inflow from the voluntary winding up of material subsidiary GSV Ophthalmics.
- Wrote off ₹43.50 lakhs following the closure of step-down subsidiary Prime Ophthalmics Products PTY Ltd on July 02, 2026.
- Total standalone expenses decreased by 30.6% YoY to ₹7.61 Cr.
GKB Ophthalmics reported a standalone revenue of ₹6.40 Cr for Q1 FY27, a 27.6% decline from ₹8.84 Cr in the same quarter last year. The company is currently contesting a significant legal demand of ₹8.82 Cr from the Labour Commissioner, which represents approximately 16.6% of its net worth (₹53 Cr). Additionally, the company has closed its non-performing Australian step-down subsidiary, writing off an investment of AED 1,69,325.58. While standalone net losses narrowed to ₹0.67 Cr from ₹1.88 Cr YoY, the legal dispute remains a primary concern for liquidity.
- Standalone revenue for Q1 FY27 decreased to ₹6.40 Cr from ₹8.84 Cr in Q1 FY26.
- Legal demand of ₹8.82 Cr from the Mamlatdar of Bardez Taluka challenged in High Court (Hearing: Aug 19, 2026).
- Write-off of AED 1,69,325.58 following the closure of Prime Ophthalmics Products PTY Limited on July 02, 2026.
- Standalone net loss narrowed to ₹0.67 Cr for the quarter ended June 30, 2026, compared to ₹1.88 Cr loss YoY.
- Prescription Optical Products LLC (POPL) restructured into a Wholly Owned Subsidiary of the Sharjah-based FZE unit.
GKB Ophthalmics has scheduled its 44th Annual General Meeting (AGM) for August 28, 2026, to review the performance of FY 2025-26. The company has dispatched letters to shareholders without registered email addresses, providing a direct web-link to the Annual Report. This follows a turnaround year where the company reported a Net Profit of ₹3.0 cr in FY26, recovering from a ₹7.0 cr loss in FY25. The filing also serves as a regulatory reminder for shareholders to update KYC details and dematerialize physical shares to ensure receipt of future payments.
- 44th Annual General Meeting scheduled for August 28, 2026, at 11:00 AM in Goa.
- Cut-off date for identifying shareholders for this communication was July 24, 2026.
- Company reported a recovery in FY26 with Revenue of ₹149 cr and Net Profit of ₹3.0 cr.
- Mandatory KYC updates required for physical shareholders to receive dividends/payments after April 1, 2024.
- Promoter holding remains stable at 51.15% as of June 2026.
GKB Ophthalmics has announced its 44th Annual General Meeting (AGM) will be held on August 25, 2026. The register of members and share transfer books will remain closed from August 19 to August 25, 2026, for this purpose. The company explicitly stated that no dividend has been proposed for the financial year 2025-26. This follows a year where the company returned to profitability with a PAT of ₹3 Cr compared to a ₹7 Cr loss in FY25.
- 44th Annual General Meeting scheduled for August 25, 2026
- Book closure period defined as August 19, 2026, to August 25, 2026
- Zero dividend proposed for the financial year 2025-26
- Company reported a turnaround to ₹3 Cr profit in FY26 from a ₹7 Cr loss in FY25
GKB Ophthalmics has released its FY26 Annual Report, confirming a turnaround to a consolidated profit of ₹1.22 Cr from a loss of ₹7.04 Cr in FY25. Revenue grew significantly to ₹149 Cr in FY26, up from ₹109 Cr in the previous year. The company has scheduled its 44th AGM for August 25, 2026, to approve these results and re-appoint key management. Proposed re-appointments include CMD K.G. Gupta for a 3-year term starting April 2027 and Executive Director Cedric Lobo for 2 years.
- Achieved consolidated net profit of ₹1.22 Cr in FY26 compared to a ₹7.04 Cr loss in FY25
- Annual revenue increased by 36.7% to ₹149 Cr in FY26 from ₹109 Cr in FY25
- Proposed re-appointment of CMD K.G. Gupta with a basic salary of ₹3.60 lakhs per month plus 1% commission on net profits
- Proposed re-appointment of Executive Director Cedric Lobo with a remuneration range of ₹9.50 lakhs to ₹15.00 lakhs p.a.
- 44th Annual General Meeting scheduled for August 25, 2026, at the company's registered office in Goa
GKB Ophthalmics has scheduled a board meeting for August 12, 2026, to approve its standalone and consolidated financial results for the quarter ended June 30, 2026. The company is coming off a recovery phase, with TTM PAT at Rs 3 Cr compared to a full-year loss of Rs 7.0 Cr in FY25. Investors will be monitoring if the company can improve upon the Rs 0.64 Cr loss reported in the same quarter last year (June 2025). The trading window for designated persons has been closed since July 01, 2026.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results
- Trading window for equity shares closed from July 01, 2026
- Company reported TTM revenue of Rs 149 Cr against a market cap of Rs 69 Cr
- Previous year's corresponding quarter (Jun 2025) saw a net loss of Rs 0.64 Cr
GKB Ophthalmics has received a formal 'Notice of Demand' for ₹8.82 crore from the Mamlatdar of Bardez Taluka, Goa, following a long-standing labour dispute (Case No. 32/09). The notice, received on July 13, 2026, mandates the recovery of dues within a strict 10-day period. This stems from an Industrial Tribunal award dated May 25, 2021, and a subsequent recovery order by the Labour Commissioner in September 2025. The company intends to challenge this demand by filing a writ petition in the High Court of Bombay.
- Demand notice for ₹8,82,00,856 received on July 13, 2026, at 5:00 PM.
- Payment or recovery of the full amount is required within a 10-day window.
- The dispute originates from an Industrial Tribunal Award passed on May 25, 2021.
- The Labour Commissioner had previously passed the recovery order on September 4, 2025.
- Company is seeking legal relief via a writ petition in the High Court of Bombay.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
